Feasibility and Acute Effects of Supramaximal High-Intensity Interval Training in People With COPD
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 32
- 试验地点
- 1
- 主要终点
- Exercise intensity
研究概览
简要总结
High-intensity exercise is essential for optimal development of cardiorespiratory fitness and health. This is, however, challenging for most people with chronic obstructive pulmonary disease (COPD) due to ventilatory limitations, leading to exercise at lower intensities accompanied by suboptimal stress on the cardiovascular and muscular system.
The aims of this cross-over trial is:
- To compare the acute effects of short-duration supramaximal high-intensity interval training (HIIT) vs. traditional moderate-intensity continuous training (MICT) in people with COPD and matched healthy controls (HC).
- To investigate the feasibility of supramaximal HIIT in people with COPD and matched HC.
- To compare the cardiorespiratory demand, exercise intensity and symptoms during a modified Borg Cycle Strength Test (BCST) and a cardiopulmonary exercise test (CPET) in people with COPD and HC.
详细描述
In this study, eligible participants attended the facility four times within 14 days with at least 48 hours of rest between visits.
Exercise tests (visit 1, week 1):
After pulmonary functions tests, a CPET on a stationary bicycle was performed according to international guidelines. After 1.5 hours of recovery, a BCST was performed to assess anaerobic exercise capacity and determine exercise intensities for supramaximal HIIT.
Exercise sessions (visit 2 - week 1; visit 3 - week 2; visit 4 - week 2):
The order of the two first exercise sessions (HIIT at 60% of MPO6 or MICT) on a stationary bicycle were randomized. The exercise session at HIIT at 80% of MPO6 was always the third exercise session.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Crossover
- 主要目的
- Other
- 盲法
- None
入排标准
- 年龄范围
- 40 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •COPD with non-reversible airflow obstruction diagnosis (post-bronchodilator forced expiratory volume during the first second/forced vital capacity (FEV1/FVC) < 0.7)
- •Age: > 40 years
排除标准
- •Recent exacerbation of COPD (< 6 weeks)
- •Neuromuscular, orthopaedic and/or any other condition that can compromise participation in testing
- •Recent lung cancer (< 5 years)
- •Unstable cardiac disease and/or cardiac stimulator
- •Inclusion Criteria:
- •Age: > 40 years
- •Exclusion Criteria:
- •Neuromuscular, orthopaedic and/or any other condition that can compromise participation in testing
- •Any respiratory disease
- •Recent lung cancer (< 5 years)
- •Unstable cardiac disease and/or cardiac stimulator
- •Too low or high physical activity level that prohibits matching
结局指标
主要结局
Exercise intensity
时间窗: During visit 4 (week 2)
Produced watt at the set training intensity
Brain-derived neurotrophic factor (BDNF)
时间窗: During visit 4 (week 2)
Concentration of BDNF in obtained venous blood samples before, during and after exercise. Measured as ng/mL or pg/mL.
次要结局
- Peripheral blood oxygen saturation (SpO2)(During visit 1 (CPET and BCST; week 1), visit 2 (week 1), visit 3 (week 2) and visit 4 (week 2))
- Cardiorespiratory demand(During visit 1 (CPET and BCST; week 1), visit 2 (week 1), visit 3 (week 2) and visit 4 (week 2))
- Venous blood lactate concentration(During visit 2 (week 1), visit 3 (week 2) and visit 4 (week 2))
- Session RPE(During visit 2 (week 1), visit 3 (week 2) and visit 4 (week 2))
- Exercise intensity(During visit 1 (BCST; week 1))
- Rating of perceived exertion(During visit 1 (CPET and BCST; week 1), visit 2 (week 1), visit 3 (week 2) and visit 4 (week 2))
- Exercise preference(At the end of visit 3 (week 2))
- Rating of symptoms(During visit 1 (CPET and BCST; week 1), visit 2 (week 1), visit 3 (week 2) and visit 4 (week 2))
- Blood pressure(During visit 1 (CPET and BCST; week 1), visit 2 (week 1), visit 3 (week 2) and visit 4 (week 2))
- Circulating levels of neurotrophic factors(During visit 2 (week 1), visit 3 (week 2) and visit 4 (week 2))
- Exercise session completion(During visit 2 (week 1), visit 3 (week 2) and visit 4 (week 2))
- Circulating levels of exerkines(During visit 2 (week 1), visit 3 (week 2) and visit 4 (week 2))
- Exercise capacity(During visit 1 (CPET; week 1))
- Adverse events(During visit 2 (week 1), visit 3 (week 2) and visit 4 (week 2))
研究者
Andre Nyberg
Associate Professor
Umeå University